Fox Run Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Fox Run Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,117	Closed	-$73K	–	538
2019 Q1	$73K	Sell	13,117 -5,083	-28%	-$30.9K	0.04%	430
2018 Q4	$121K	Sell	18,200 -7,009	-28%	-$56.8K	0.06%	456
2018 Q3	$269K	Sell	25,209 -13,066	-34%	-$150K	0.12%	385
2018 Q2	$459K	Sell	38,275 -6,998	-15%	-$71.6K	0.15%	280
2018 Q1	$388K	Buy	+45,273	New	+$419K	0.09%	403
2017 Q4	–	Sell	-30,600	Closed	-$376K	–	787
2017 Q3	$376K	Buy	+30,600	New	+$452K	0.11%	404
2017 Q2	–	Sell	-10,300	Closed	-$148K	–	735
2017 Q1	$148K	Sell	10,300 -11,900	-54%	-$177K	0.06%	516
2016 Q4	$307K	Buy	+22,200	New	+$356K	0.16%	279
2016 Q3	–	Sell	-19,100	Closed	-$274K	–	598
2016 Q2	$274K	Buy	+19,100	New	+$259K	0.13%	327

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Fox Run Management's LXRX Position: Q2 2019 in Review

Fox Run Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2019, closing a stake of 13,117 shares — an estimated $73K sold.

Fox Run Management first reported a position in LXRX in Q2 2016 and held it in 9 quarters. The position peaked at $459K in Q2 2018. 109 funds tracked by Wall St. Rank hold LXRX as of Q2 2019.

Fox Run Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Fox Run Management sold 13,117 Lexicon Pharmaceuticals shares in Q2 2019, an estimated $73K.
Fox Run Management first reported a position in Lexicon Pharmaceuticals in Q2 2016 and held it in 9 quarters.
Fox Run Management's Lexicon Pharmaceuticals position peaked at $459K in Q2 2018.
109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2019.

Based on Fox Run Management's 13F filing for Q2 2019, filed 17 Jul 2019.